Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses
Pre-publication versions of this article are available by contacting email@example.com.
|25 May 2018||Submitted||Original manuscript|
|15 Aug 2018||Reviewed||Reviewer Report - Reza Elaidi|
|22 Aug 2018||Reviewed||Reviewer Report - Ian Davis|
|21 Sep 2018||Author responded||Author comments - Irina Proskorovsky|
|Resubmission - Version 2|
|21 Sep 2018||Submitted||Manuscript version 2|
|24 Sep 2018||Reviewed||Reviewer Report - Ian Davis|
|2 Nov 2018||Reviewed||Reviewer Report - Reza Elaidi|
|27 Nov 2018||Author responded||Author comments - Irina Proskorovsky|
|Resubmission - Version 3|
|27 Nov 2018||Submitted||Manuscript version 3|
|29 Nov 2018||Editorially accepted|
|19 Dec 2018||Article published||10.1186/s12885-018-5157-0|
How does Open Peer Review work?
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting firstname.lastname@example.org.
You can find further information about the peer review system here.